The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
The Seattle-based company is one of several that have raised venture capital and equity investment funding this week.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.